Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
5-day change
1st Jan Change
137.2
USD
+3.13%
+0.57%
+73.80%
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to TransMedics Fir...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
CL King Initiates TransMedics at Buy Rating With $161 Price Target
Jun. 07
MT
Transmedics Group Insider Sold Shares Worth $393,986, According to a Recent SEC Filing
Jun. 05
MT
Transmedics Group Insider Sold Shares Worth $280,016, According to a Recent SEC Filing
Jun. 05
MT
Stephens Initiates TransMedics at Overweight Rating With $151 Price Target
Jun. 04
MT
Stephens Starts TransMedics Group With Overweight Rating, $151 Price Target
Jun. 04
MT
Transmedics Group Insider Sold Shares Worth $3,902,100, According to a Recent SEC Filing
May. 08
MT
Transmedics Group Insider Sold Shares Worth $759,479, According to a Recent SEC Filing
May. 08
MT
Transmedics Group Insider Sold Shares Worth $930,278, According to a Recent SEC Filing
May. 08
MT
Transmedics Group Insider Sold Shares Worth $1,920,000, According to a Recent SEC Filing
May. 08
MT
Transmedics Group Insider Sold Shares Worth $7,986,219, According to a Recent SEC Filing
May. 03
MT
Transmedics Group Insider Sold Shares Worth $1,600,633, According to a Recent SEC Filing
May. 03
MT
TransMedics Group Shares Rise as Q1 Swings to Net Income, Revenue Rises; Increases 2024 Revenue Outlook
May. 01
MT
Oppenheimer Adjusts TransMedics Group Price Target to $125 From $105, Maintains Outperform Rating
May. 01
MT
Earnings Flash (TMDX) TRANSMEDICS GROUP Posts Q1 Revenue $96.9M, vs. Street Est of $83.8M
Apr. 30
MT
TransMedics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 30
CI
Transcript : TransMedics Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024
Apr. 30
TransMedics Group, Inc. Raises Revenue Guidance for the Full Year 2024
Apr. 30
CI
Transmedics Group Insider Sold Shares Worth $380,480, According to a Recent SEC Filing
Apr. 18
MT
Transmedics Group Insider Sold Shares Worth $802,084, According to a Recent SEC Filing
Apr. 05
MT
Transmedics Group Insider Sold Shares Worth $1,110,150, According to a Recent SEC Filing
Apr. 02
MT
Piper Sandler Initiates TransMedics Group With Overweight Rating, $95 Price Target
Mar. 28
MT
Oppenheimer Adjusts TransMedics Group Price Target to $105 From $92, Maintains Outperform Rating
Feb. 27
MT
Top Premarket Gainers
Feb. 27
MT
Transcript : TransMedics Group, Inc., Q4 2023 Earnings Call, Feb 26, 2024
Feb. 26
TransMedics Group Swings to Net Income in Q4, Revenue Increases; Sets 2024 Revenue Outlook-- Shares Rise
Feb. 26
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
More about the company
Last Close Price
137.2
USD
Average target price
135
USD
Spread / Average Target
-1.59%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1